In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| 8-K | 10-K | 10-K | S-1/A | S-1 |
Revenues | 19.0 | 0.0 | 0.0 | 6.5 | 6.5 |
Revenue growth | | | -100.0% | 0.0% | |
Cost of goods sold | 19.0 | 0.0 | 0.0 | 13.0 | 8.5 |
Gross profit | 0.0 | 0.0 | 0.0 | -6.5 | -2.0 |
Gross margin | 0.0% | | | -100.0% | -30.7% |
Selling, general and administrative [+] | 11.5 | 6.4 | 2.7 | 2.0 | 2.0 |
General and administrative | | 6.4 | 2.7 | 2.0 | 2.0 |
Research and development | | 13.4 | 8.4 | | |
Other operating expenses | 19.0 | | | | 4.5 |
EBITDA [+] | | -19.7 | -11.1 | -8.5 | |
EBITDA growth | 54.4% | 77.8% | 30.5% | -0.1% | |
EBITDA margin | -160.4% | | | -130.5% | -130.7% |
Depreciation and amortization | | 0.1 | 0.0 | 0.0 | |
EBIT [+] | -30.5 | -19.8 | -11.1 | -8.5 | -8.5 |
EBIT growth | 53.8% | 78.3% | 30.5% | 0.0% | |
EBIT margin | -160.4% | | | -130.7% | -130.7% |
Interest expense, net [+] | | 0.9 | 1.0 | | |
Interest expense | | 0.9 | 1.0 | | |
Interest income | | 0.0 | 0.0 | | |
Other income (expense), net [+] | 0.1 | -1.1 | -0.9 | -6.0 | -6.0 |
Gain (loss) on debt retirement | | 0.4 | | | |
Gain (loss) on derivative instruments | | 0.1 | 0.6 | | |
Unrealized gain/loss on derivatives | | -1.6 | -1.5 | | |
Change in fair value of warrants | | -1.6 | -1.5 | | |
Pre-tax income | -30.3 | -21.8 | -13.0 | -14.5 | -14.5 |
Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net income | 0.0 | -24.3 | -21.9 | -14.5 | -14.5 |
Net margin | -0.2% | | | -222.3% | -222.3% |
|
Basic EPS [+] | ($0.92) | ($0.92) | ($6.85) | ($9.18) | ($9.18) |
Growth | -0.5% | -86.5% | -25.3% | 0.0% | |
Diluted EPS [+] | ($0.92) | ($0.92) | ($6.85) | ($9.18) | ($9.18) |
Growth | -0.5% | -86.5% | -25.3% | 0.0% | |
|
Shares outstanding (basic) [+] | 0.0 | 26.3 | 3.2 | 1.6 | 1.6 |
Growth | -99.9% | 721.4% | 102.9% | 0.0% | |
Shares outstanding (diluted) [+] | 0.0 | 26.3 | 3.2 | 1.6 | 1.6 |
Growth | -99.9% | 721.4% | 102.9% | 0.0% | |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |